Đánh giá kết quả phác đồ Etoposide kết hợp nhóm Platinum điều trị ung thư phổi tế bào nhỏ giai đoạn lan tràn tại Bệnh viện Bạch Mai

To evaluate the results of the Etoposide regimen combined with the Platinum group in the treatment of extensive stage small cell lung cancer, and to comment on some undesirable effects of the regimen. Subjects: Including 36 patients with extensive stage small cell lung cancer from January 2021 to January 2023. Methods: Retrospective descriptive study. Results: The average age was 64.3 years old, mostly male. Regarding the improvement of functional symptoms: the majority of patients had stable disease after treatment (58.3%). According to RECIST criteria, the proportion of patients with partial response was the majority (52.8%), complete response (19.4%), progressive disease (19.4%), and stable disease (8.3%). Hematological adverse effects were only mild (grade I-II), the most common side effects were vomiting, nausea and pneumonia with rates of 33.3% and 13.9%, respectively. Conclusions: Extensive stage small cell lung cancer is common in men, the Etoposide regimen combined with platinum group showed good effectiveness, toxicity was usually mild.